UCB Just Dropped $2.2 Billion on a Company That Didn't Exist Two Years Ago

Phase 2 studies in myasthenia gravis and interstitial lung disease are planned next for cizutamig.

UCB's Immunology Shopping Spree

This isn't a one-off for UCB. The Belgian pharma company has been on an absolute tear in 2026:

• March 2026: Licensed a B-cell TCE from Antengene for $80 million upfront, with up to $1.1 billion in milestones.
• April 2026: Acquired Neurona Therapeutics for up to $1.15 billion.
• May 2026: The Candid deal.

That's roughly $3.35 billion in potential deal value across three transactions in about two months. UCB's CEO Jean-Christophe Tellier has called these moves "pivotal" for redefining treatment standards, and the company clearly believes TCEs represent the next wave of care for immunological conditions.

What's notable: UCB didn't change its 2026 financial guidance after announcing the Candid acquisition. They're still projecting high single-digit to low double-digit revenue growth. Translation: they can afford this.

Why Everyone Wants These Assets

UCB isn't the only one chasing this thesis. The autoimmune TCE space has become a land grab.

In January 2026 alone, Sanofi entered a strategic collaboration with Earendil Labs worth up to $2.56 billion (an AI platform for autoimmune drugs), Eli Lilly entered a strategic collaboration with Repertoire Immune Medicines worth up to $1.84 billion in milestones, and Boehringer Ingelheim struck a licensing deal worth €1.05 billion on a bispecific from Simcere. Earlier, in 2025, AbbVie paid $2.1 billion for Capstan's anti-CD19 CAR-T program.

The logic driving all of this is simple. CAR-T therapy has produced jaw-dropping results in small autoimmune studies: patients with refractory lupus going into complete remission after a single treatment. But CAR-T is expensive, complex, and requires manufacturing a custom product for each patient. TCEs could deliver similar immune-reset biology as a standard injectable drug. If that works at scale, it would be transformative for millions of patients with diseases like lupus, rheumatoid arthritis, and myasthenia gravis.

The catch? Most of these programs are still in Phase 1. We're betting on early signals, not definitive proof. CRS remains a risk. And paying $2 billion for Phase 1 assets requires enormous confidence in the platform.

The Rallybio Plot Twist

One entertaining detail: Candid had announced a reverse merger with Rallybio in early March 2026. That merger would have taken Candid public. Instead, UCB swooped in, the Rallybio merger was terminated on May 3, 2026, and Candid will pay Rallybio a $50 million termination fee for walking away.

Imagine planning your wedding and then getting a better proposal the next day. Awkward for Rallybio, but $50 million in breakup money isn't nothing.

The Bottom Line

UCB is making a concentrated bet that T-cell engagers will do for autoimmune diseases what checkpoint inhibitors did for cancer: create a new standard of care across dozens of conditions. They're building a portfolio of assets designed to hit different B-cell populations (BCMA for plasma cells, CD20 for broader B-cells), giving them multiple shots on goal.

The risk is obvious. Phase 1 data is encouraging but far from conclusive. Two billion dollars is a staggering price for a company with zero approved products and less than two years of existence. But if the immune reset thesis holds up in larger trials, UCB could own a defining franchise in immunology for the next decade.

Ken Song, meanwhile, has now founded or led companies that sold for a combined $6.3 billion. Not bad for someone who was technically unemployed in mid-2024.

The FDA Just Killed the 60-Year-Old Way We Run Clinical Trials

The FDA is letting Amgen and AstraZeneca stream clinical trial data to regulators in real time, ditching the decades-old "run the study, then submit everything" model. If it works, drug development timelines could compress by months, and the entire industry will want in.